Science is our goal. We are not a CRO. We only run studies with strategies and molecules we truly believe in. ▪ Agility in bureaucracy with agencies, steering committees and vendors is key so that we can adapt the initial plan when new risks are identified. Also, as the sponsor we can streamline the management of the clinical trial. ▪ We favor a collaborative approach for clinical research. Even if MEDSIR acts as the Sponsor, collaborating companies are involved in all relevant scientific and operational decisions, and can even be part of the Steering Committee. Likewise, the final trial database is fully shared with collaborating companies. ▪ Acting as a Sponsor allows us not to charge consultant fees since technically, we are asking for financial support from the company to run a MEDSIR study. ▪ Some operational costs can be reduced for independent studies in which the sponsor has no commercial interest.

▪ The data collected in a clinical trial belongs to the Sponsor. However, we are willing to grant full access to all the data generated in the trial (not only published results, but the full database) to collaborating companies in perpetuity and free of any additional charges. ▪ All exploitation rights belong to the collaborating company. We are completely independent and have no commercial interests in the result of the trial. The company has access to any data needed for potential submissions to regulatory agencies. ▪ We maintain publication rights for the trial results, but the collaborating company can be included if they choose. ▪ We are interested in science. We might want to generate additional research/publications with the data collected, but we will never do it without the company’s knowledge.

▪ We have a global operational structure. ▪ We have a flexible model which is not limited to any pre-defined network of sites and/or investigators. We involve the sites that make more sense for each particular project. ▪ We believe in collaborative clinical research. We want to consider the strategic needs of collaborating companies and are willing to involve them in all relevant decisions regarding the design and management of the project. ▪ We strive to professionalize independent clinical research applying industry quality standards. ▪ We are very agile in the presentation and development of potential ideas. Time is of the essence in the volatile field of clinical development in oncology.

▪ We generate added value with our scientific expertise through the initial idea generation and design. ▪ We present closed budgets with shared risk, so trial speed is in our own interest. ▪ Our model streamlines clinical research to increase speed and reduce costs. ▪ We are very proactive in controlling risks and adapting the operational plan to changing needs, if needed. We are fighting for OUR STUDY. ▪ We guarantee the full engagement of KOLs who thoroughly believe in the scientific and clinical potential of the proposals they help develop. ▪ We understand that time spent from first idea generation until start-up is crucial (maybe even more so than accrual speed).

Our team is available when you need it. Just fill out this form, and we will contact you as soon as possible.